Based on the key indicators related to Vertex Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Vertex Pharmaceuticals is performing exceptionally good at this time. It has a great odds to report excellent financial results in December. At this time, Vertex Pharmaceuticals' Cash And Short Term Investments are fairly stable compared to the past year. Liabilities And Stockholders Equity is likely to rise to about 23.9 B in 2024, despite the fact that Net Debt is likely to grow to (9.1 B). Key indicators impacting Vertex Pharmaceuticals' financial strength include:
The essential information of the day-to-day investment outlook for Vertex Pharmaceuticals includes many different criteria found on its balance sheet. An individual investor should monitor Vertex Pharmaceuticals' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Vertex Pharmaceuticals.
Net Income
3.8 Billion
Vertex
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Other Non Cash Items
Change To Liabilities
Change To Account Receivables
Stock Based Compensation
Other Cashflows From Investing Activities
Change To Inventory
Total Cashflows From Investing Activities
Sale Purchase Of Stock
Dividends Paid
Investments
Change Receivables
Net Borrowings
Exchange Rate Changes
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change To Netincome
Change To Operating Activities
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Short Term Debt
Accounts Payable
Property Plant And Equipment Gross
Accumulated Other Comprehensive Income
Net Receivables
Common Stock Total Equity
Common Stock
Other Assets
Long Term Debt
Short Term Investments
Property Plant Equipment
Other Liab
Current Deferred Revenue
Inventory
Good Will
Intangible Assets
Net Tangible Assets
Total Permanent Equity
Noncontrolling Interest In Consolidated Entity
Retained Earnings Total Equity
Long Term Debt Total
Capital Surpluse
Additional Paid In Capital
Deferred Long Term Liab
Non Current Liabilities Other
Capital Lease Obligations
Short Long Term Debt
Long Term Investments
Net Invested Capital
Net Working Capital
Capital Stock
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Ebitda
Total Operating Expenses
Income Tax Expense
Depreciation And Amortization
Cost Of Revenue
Income Before Tax
Total Other Income Expense Net
Research Development
Interest Expense
Selling General Administrative
Extraordinary Items
Net Income From Continuing Ops
Non Recurring
Non Operating Income Net Other
Net Income Applicable To Common Shares
Minority Interest
Tax Provision
Interest Income
Net Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Vertex Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Vertex Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Vertex Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Vertex Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Vertex Pharmaceuticals. Check Vertex Pharmaceuticals' Beneish M Score to see the likelihood of Vertex Pharmaceuticals' management manipulating its earnings.
Vertex Pharmaceuticals Stock Summary
Vertex Pharmaceuticals competes with Biomarin Pharmaceutical, Sarepta Therapeutics, Alnylam Pharmaceuticals, Intellia Therapeutics, and Editas Medicine. Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 00 people.
Foreign Associate
Mexico
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Vertex Pharmaceuticals Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
Cash flow analysis captures how much money flows into and out of Vertex Pharmaceuticals. It measures of how well Vertex is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Vertex Pharmaceuticals brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Vertex had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Vertex Pharmaceuticals has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
Comparative valuation techniques use various fundamental indicators to help in determining Vertex Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Vertex Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Vertex Pharmaceuticals competition to find correlations between indicators driving Vertex Pharmaceuticals's intrinsic value. More Info.
Vertex Pharmaceuticals is rated below average in return on equity category among its peers. It is rated first in return on asset category among its peers . At this time, Vertex Pharmaceuticals' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Vertex Pharmaceuticals' earnings, one of the primary drivers of an investment's value.
Vertex Pharmaceuticals' Earnings Breakdown by Geography
Vertex Pharmaceuticals Systematic Risk
Vertex Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Vertex Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Vertex Pharmaceuticals correlated with the market. If Beta is less than 0 Vertex Pharmaceuticals generally moves in the opposite direction as compared to the market. If Vertex Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Vertex Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Vertex Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Vertex Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Vertex Pharmaceuticals Thematic Clasifications
Vertex Pharmaceuticals is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Vertex Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Vertex Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Vertex Pharmaceuticals growth as a starting point in their analysis.
Vertex Pharmaceuticals November 30, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Vertex Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Vertex Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Vertex Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Vertex Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Vertex Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.